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S-nitrosothiol signals in the enteric nervous system: lessons 
learnt from big brother
Tor C. Savidge*
Division of Gastroenterology and Hepatology, The University of Texas Medical Branch, Galveston, TX, USA
Nitric oxide (NO) is a functionally important neurotransmitter signaling molecule generated by 
mammalian and bacterial nitric oxide synthases (NOS), and by chemical conversion of dietary 
nitrite in the gastrointestinal (GI) tract. Neuronal NOS (nNOS) is the most abundant isoenzyme in 
the enteric nervous system, and targeted deletion in transgenic mice has clearly demonstrated 
its importance in normal gut function. Enteric neuropathy is also often associated with abnormal 
NO production, for example in achalasia and diabetic gastroparesis. Not surprisingly therefore, 
aberrant nNOS activity is widely implicated in enteric disease, and represents a potential 
molecular target for therapeutic intervention. One physiological signaling mechanism of NO 
bioactivity is through chemical reaction with the heme center of guanylyl cyclase, resulting in 
the conversion of cGMP from GTP. This second messenger nucleotide signal activates cGMP-
dependent protein kinases, phosphodiesterases, and ion channels, and is implicated in the 
neuronal control of GI function. However, few studies in the GI tract have fully related NO 
bioactivity with specific molecular targets of NO-derived signals. In the central nervous system 
(CNS), it is now increasingly appreciated that NO bioactivity is often actively transduced via 
S-nitrosothiol (SNO) signals rather than via activation of guanylyl cyclase. Moreover, aberrant 
S-nitrosylation of specific molecular targets is implicated in CNS pathology. S-nitrosylation 
refers to the post-translational modification of a protein cysteine thiol by NO, forming an 
endogenous SNO. Because cysteine residues are often key regulators of protein function, 
S-nitrosylation represents a physiologically important signaling mechanism analogous to other 
post-translational modifications, such as O-phosphorylation. This article provides an overview 
of how neurotransmitter NO is produced by nNOS as this represents the most prominent and 
well defined source of SNO production in the enteric nervous system. Further, it provides a 
perspective of how S-nitrosylation signals derived from multiple diverse sources may potentially 
transduce NO bioactivity in the GI tract. Possible lessons that might be learnt from the CNS, 
such as SNO mediated auto-inhibition of nNOS activity and modulation of neuronal cell death, 
are also explored as these may have pathophysiological relevance in enteric neuropathy. Thus, 
S-nitrosylation may mediate previously underappreciated NO-derived signals in the enteric 
nervous system that regulate homeostatic gut functions and disease susceptibility.
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at various levels in neurons and glia of the central and enteric 
nervous systems. However, nNOS is the predominant physiologi-
cal isoenzyme in these tissues (Jaffrey et al., 2001) and forms an 
active homodimer to generate free NO by a process that is regu-
lated by several cofactors including heme, flavin mononucleotide 
(FMN), flavin adenine dinucleotide (FAD), and tetrahydrobiopt-
erin (Wang et al., 1999; Gangula et al., 2007; Foster et al., 2009).
In the enteric nervous system, nNOS-derived NO is an important 
neurotransmitter regulator of motility, vascular tone, blood supply, 
mucosal secretion, and barrier function (Bornstein et al., 2010). An 
emerging concept in the NO signaling field is that second messenger 
S-nitrosothiols (SNOs) play a crucial regulatory role in this cellular 
signal transduction process (Benhar et al., 2009). Preliminary stud-
ies of nNOS signaling in the enteric nervous system support this 
view (Vanden Berghe, 2008), and possibly implicate S-nitrosylation 
as a major signaling mechanism of NO neurotransmitter activity 
in the gastrointestinal (GI) tract. Consequently, this article will 
Nitric oxide (NO)-related biology was first described in the 1980s 
with the demonstration of free NO gas release during cellular 
metabolism (Murad, 1986; Ignarro et al., 1987). Following these 
initial reports, NO has become one of the most intensely studied 
cellular signaling molecules with more than a 100,000 related 
publications reported to date. NO is a highly reactive free radical 
gas with diverse physiological functions that are mediated via 
intracellular and intercellular communications (Ignarro, 1996; 
Andrew and Mayer, 1999; Li and Poulos, 2005). Numerous disease 
processes are also associated with pathological NO production 
(Foster et al., 2009). One important cellular source of NO is from 
l-arginine synthesis by P-450-like nitric oxide synthases (NOS), 
in the presence of oxygen and nicotinamide adenine dinucleotide 
phosphate (NADPH) co-substrates (Moncada and Higgs, 1993). 
Several genetically distinct NOS isoenzymes exist and are desig-
nated as neuronal NOS (nNOS), endothelial NOS (eNOS), and 
inducible NOS (iNOS), respectively. These proteins are expressed 
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TranscripTional regulaTion of nnos
The genomic organization of nNOS is known and although 
canonical TATA and CCAAT boxes are absent in proximal 
regions upstream of the transcription start sites, the promoter 
region contains several putative transcription factor binding sites 
for Sp-1, AP-1, NFκB, E-box, and half sites of glucocorticoid 
response elements (Jeong et al., 2000; Molero et al., 2002; Garban 
et al., 2005). Although the absence of a TATA box does not nec-
essarily affect transcription rates, it can result in promiscuous 
initiation of transcription by RNA polymerase II, resulting in 
multiple initiation sites. In several eukaryotic genes, it has been 
observed that promoters lacking a TATA box are recognized by 
Sp-1. In this regard, because the minimal promoter of nNOS exon 
1c is GC-rich, TATA-less, and Sp-regulated, it resembles those 
for other constitutively expressed genes (including eNOS), where 
promoter regulation is poorly understood (Böhm et al., 1995; Wu, 
2002). In addition, it has been shown that Sp-1 actively interacts 
with multiple components of the transcriptional machinery in 
GC-rich promoter regions that lack a canonical TATA box (Cook 
et al., 1999). Therefore Sp-1 plays a critical role in the assembly 
of the transcription initiation complex and although not yet 
demonstrated, it is also feasible that nNOS is transcriptionally 
regulated (possibly repressed) by SNO, because this is a major 
regulator of Sp-1 activity (Zaman et al., 2004; see nNOS-Derived 
SNO and Intestinal Disease). It is likely that the presence of 
multiple alternative promoters permits cell-, tissue-, and site-spe-
cific transcriptional regulation of nNOS activity under  different 
physiological and pathological states.
focus on nNOS expression and activity as a cellular source of SNO 
in the enteric nervous system, and how these NO-derived signals 
are altered in disease states.
regulaTion of nnos acTiviTy as a cellular source of 
sno in The enTeric nervous sysTem
Neuronal NOS is abundantly expressed throughout the enteric 
nervous system where it represents the predominant source of 
NO neurotransmitter (Takahashi, 2003; Van Geldre and Lefebvre, 
2004; Bornstein et al., 2010). Within the myenteric plexus, nNOS 
activity is also associated with a significant production of cellular 
SNO (Figure 1). Therefore, the regulated activity of nNOS likely 
plays an important functional role in the GI tract, as is indicated 
by circadian correlates in nNOS expression, NO production and 
rhythmic changes in colonic motility (Hoogerwerf, 2010). Several 
functionally distinct 5′ mRNA nNOS splice variants have been iden-
tified, reflecting differential expression from alternative promoters. 
Because of this differential first exon usage and alternative splicing, 
nNOS is classified as a complex gene (Boissel et al., 2003; Newton 
et al., 2003; Secondo et al., 2003). Specific splice variants encode 
for distinct nNOS
α
, nNOSβ, or nNOSγ transcripts (Figure 2), which 
show differences in developmental and cephalocaudal expression 
in the enteric nervous system (Huber et al., 1998; Saur et al., 2000; 
Vannucchi et al., 2002). For example, all nNOS splice variants are 
expressed in the human colon, whereas the nNOSγ isoform is not 
detected in the stomach or small intestine (Stricker et al., 1997; 
Saur et al., 2002).
Figure 1 | Schematic representation (top) of nNOS activity generating 
SNO from l-arginine or from exogenous nitrite. This synthesis step may 
involve direct protein–protein interactions with nNOS or another SNO-
synthase, transfer of a coordinated NO from a transition metal center, or by 
chemical reaction with a reactive nitrosium ion intermediate. (Bottom) shows 
anti-SNO immunoreactivity in the mouse small intestinal myenteric plexus 
(scale bar = 40 μm).
Figure 2 | Schematic representation (top) of nNOS
α
 PDZ domain-
interactions with PSD-95 and the NMDA receptor in the CNS. Calcium ion 
entry activates nNOS production of NO. Excessive NO production results in 
the auto-S-nitrosylation and inhibition of nNOS and the NMDA receptor. 
Although auto-S-nitrosylation of nNOS represents a likely inhibitory 
mechanism in the GI tract, a physiological role for NMDA receptor signaling 
remains controversial. (Bottom) Shows the various nNOS protein isoforms; 
nNOS
α
 contains a NH2-terminus PDZ/GLGF-domain (∼100 amino acids), that 
modulates interactions with other PDZ-containing proteins. nNOSβ and nNOSγ 
lack a PDZ domain; H, heme consensus site; Ca, calmodulin consensus site; 
FMN, flavin mononucleotide consensus site; and FAD, flavin adenine 
dinucleotide consensus site.
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nnos splice varianTs are funcTionally disTincT
Functionally, the nNOS
α 
protein isoform is unique in that it con-
tains a specific N-terminus PDZ domain, which is important for 
protein–protein interactions that are required for homodimeriza-
tion into the active configuration (Brenman et al., 1996; Hashida-
Okumura et al., 1999; Riefler and Firestein, 2001; Chanrion et al., 
2007; Figure 2). By contrast, both nNOSβ and nNOSγ are N-terminus 
truncated proteins, and thus lack these protein–protein interaction 
domains. A recent study has highlighted the functional impor-
tance of this PDZ domain interaction in regulating nNOS activity 
in the stomach (Gangula et al., 2007). Reduced nNOS
α
 dimeriza-
tion, but not total nNOS expression, significantly altered gastric 
antrum nitrergic relaxation and solid gastric emptying resulting 
in gastroparesis. The lack of a dimerization domain in nNOSβ and 
nNOSγ suggests that these splice variants play different physiologi-
cal roles to nNOS
α
 (Figure 2). The catalytic activity of nNOSβ is 
approximately 80% of nNOS
α
, whereas nNOSγ is functionally inert 
and, as such, may function as a dominant-negative nNOS variant 
in the human colon (Brenman et al., 1996; Gangula et al., 2007). 
For example, nNOS
α
, but not nNOSβ appears to regulate pyloric 
sphincter relaxation and gastric stasis with delayed gastric empty-
ing (Gangula et al., 2007). This view is supported by findings in 
nNOS
α
 mutant mice where animals display a disease phenotype 
that closely resembles hypertrophic pyloric stenosis, with delayed 
gastric emptying of solids and fluids (Huang et al., 1993; Mashimo 
et al., 2000). Because of the continued expression of the alternative 
nNOSβ splice variant in nNOSα mutant mice, the disease pathology 
in other GI regions is less severe when compared for example with 
targeted deletion of NO-sensitive guanylyl cyclase in mice (Friebe 
et al., 2007). Differences in the N-terminus protein structure are 
therefore likely to confer functional distinctions between nNOS
α
, 
nNOSβ, and nNOSγ variants.
In the central nervous system (CNS), the PDZ domain in nNOS
α
 
also interacts with other functionally important regulatory pro-
teins, such as the postsynaptic density protein PSD-95 which 
promotes cellular calcium ion entry by binding to the glutamate-
activated N-methyl-d-aspartic acid (NMDA) receptor (Figure 2). 
nNOS (like eNOS) activity is promoted by elevated intracellular 
calcium ion concentrations. The functional regulation of nNOS
α
 
is complex as the N-terminus region also possesses a binding 
domain for nNOS protein inhibitor (PIN) and nitric oxide synthase 
interacting protein (NOSIP; Stricker et al., 1997). Moreover, these 
 protein–protein interactions with nNOS are negatively regulated 
by auto-S-nitrosylation as a form of feed-back inhibition (Jaffrey 
et al., 2001; Benhar et al., 2009; Figure 2; see SNO Effector Signals 
in the Enteric Nervous System).
sno effecTor signals in The enTeric nervous sysTem
The previous section detailed nNOS as a major (but not exclusive) 
enzymatic source for the generation of cellular SNO in the enteric 
nervous system. This section considers whether SNO may extend 
or potentiate nitrergic neurotransmission in the GI tract through 
the process of transnitrosylation. Endogenous SNO moieties are 
formed when NO reacts with the sulfur atom of cysteine resi-
dues on proteins or peptides resulting in an S–NO bond (Hogg, 
2002; Gaston et al., 2003; Figure 1). S-nitrosylation may also occur 
following transfer of an NO moiety from cysteine-to-cysteine 
 residues in a process known as transnitrosylation. S-nitrosylation 
is now known to post-translationally modify several hundreds 
of different cellular proteins (Stamler and Hess, 2010), and can 
regulate virtually all known cellular signaling cascades, ranging 
from inhibitory protein–DNA interactions (Li et al., 2007), to 
G-protein coupled receptor activation (Chvanov et al., 2006), 
and ion channel modulation (Foster et al., 2009). Small peptide 
SNOs, notably S-nitrosoglutathione (GSNO) is a potent endog-
enous transnitrosylating species, and preliminary studies in the 
GI tract have indicated that exogenous GSNO provides novel 
disease-attenuating signals in fulminant jejuno-ileitis resulting 
from functional ablation of the enteric nervous system (Savidge 
et al., 2007), burn-induced gut trauma (Costantini et al., 2010), 
and shigellosis (Flamant et al., 2010).
s-niTrosylaTion moTif
Protein S-nitrosylation is not a random event, but is most often 
governed by an exposed consensus motif that encompasses the 
cysteine residue targeted for posttranslational modification. 
Mechanistically, this S-nitrosylation motif was initially thought to 
promote cysteine thiolate nucleophilicity to NO reactivity (Stamler 
et al., 1997), but it has more recently been demonstrated that the 
motif actively promotes catalytic protein–protein interactions in 
a manner similar to the reaction between phosphokinase enzymes 
and their protein target substrates (Doullas et al., 2010; Kornberg 
et al., 2010; Liu et al., 2010; Marino and Gladyshev, 2010; Stamler 
and Hess, 2010). This makes sense in light that NO is by itself a poor 
S-nitrosylating agent, although this reaction is favored following 
an electrophilic attack of a nitrosonium ion equivalent (NO+) on 
the thiolate anion (Figure 1). It is currently proposed that SNO– 
protein intermediates generated as a result of NOS activity may also 
function as specific SNO-synthases in cellular compartments that 
normally lack NOS activity, for example glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH)–SNO in the nucleus specifically 
transnitrosylates deacetylating enzyme sirtuin-1 (SIRT-1), his-
tone deacetylase-2 (HDAC2), and DNA-activated protein kinase 
(DNA-PK; Kornberg et al., 2010; Stamler and Hess, 2010). Because 
the SNO-synthases appear to target multiple protein substrates, 
intensive efforts are currently underway to fully characterize the 
complete SNO-synthase network, and this may now easily exceed 
the known repertoire of phosphokinases. Denitrosylating enzyme 
activities in the form of thioredoxin, Cu2+, Zn2+ superoxide dis-
mutase, GSNO-reductase, and carbonyl reductase (Benhar et al., 
2009; Staab et al., 2011) are more clearly defined, and it is perhaps 
not a coincidence that aberrant regulation of these enzymatic path-
ways is often associated with disease induction.
Structurally, the S-nitrosylation motif is encoded either into 
the primary amino acid sequence of a protein, or it may forma 
more integral part of the tertiary structure. For example, the 
ryanodine response calcium channel of skeletal muscle has many 
reduced cysteines, yet only one cysteine (Cys3635) forming part 
of an S-nitrosylation motif is selectively modified by calmodulin-
dependent NO-mediated modulation of channel activity (Xu et al., 
1998). The tertiary S-nitrosylation motif is often also allosterically 
regulated, thereby conferring an additional level of physiological 
control, for example via redox or ion-dependent reactions that 
modify the protein structure. An example is the S-nitrosylation of 
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been identified on both CNS and enteric neurons (Liu et al., 1997) 
it is feasible that this constitutes a common regulatory mechanism 
for nNOS activity and neuronal plasticity, although this remains a 
contentious issue in the enteric nervous system (Ren et al., 2000). 
Notably, NMDA receptor stimulation of nNOS in the CNS results 
in S-nitrosylation of stargazin, a physiological regulator of AMPA 
receptor expression on the surface of neurons (Selvakumar et al., 
2009). S-nitrosylation agents are also known to inhibit the activity 
of the epidermal growth factor receptor (EGFR), as well as several 
G-protein-coupled receptors, including the serotonin 5-HT
2
 recep-
tor (Foster et al., 2009). Moreover, the activity of several voltage-
gated, cation-activated, and receptor-coupled ion channels have 
been shown to be modulated by endogenous SNOs, although the 
regulatory cysteine residues that are functionally important in alter-
ing many of these channel activities remain to be fully character-
ized (Sun et al., 2006; Whalen et al., 2007). Neuromodulation by 
SNO’s may also target neuropeptides. For example, S-nitrosylation 
of vasointestinal peptide (VIP) augments the relaxations it evokes 
in smooth muscle cells (Jia and Stamler, 1999).
Target protein interaction with NOS or other SNO-synthases 
represents another important regulatory mechanism, for example 
activation of cyclooxygenase-2 is facilitated by the binding and 
subsequent S-nitrosylation by iNOS (Kim et al., 2005). In regard to 
neuronal NO signaling, PDZ domain-interactions appear to play a 
particularly important role in self-limiting nNOS enzymatic activ-
ity. Excessive NO production leads to auto-S-nitrosylation of nNOS, 
causing down-regulation of its enzymatic activity. S-nitrosylation 
of the NMDA receptor binding partner also occurs as a means 
of self-regulation in the CNS (Figure 2). Moreover, the neuronal 
NMDA receptor mediates the postsynaptic Ca2+ flux which is a 
regulatory requirement for nNOS activity (Selvakumar et al., 2009). 
The NMDA receptor is in turn S-nitrosylated on a single critical 
cysteine (Cys399) on the NR2A subunit, which inhibits the regula-
tory Ca2+ flux. Mechanistically, S-nitrosylation of the NMDA recep-
tor by nNOS appears to inhibit its channel function by allosterically 
sensitizing the receptor complex to Zn2+ inhibitory modulators. In 
summary, it is possible that S-nitrosylation plays an important and 
largely unexplored role in transducing NO-derived signals in the 
GI tract, as has become increasingly evident in the CNS and other 
organs (Foster et al., 2009; Stamler and Hess, 2010).
nnos-derived sno and inTesTinal disease
The previous sections have detailed nNOS activity as a major 
enzymatic source of NO and SNO in the enteric nervous system. 
Several reports have directly implicated aberrant NO activity in 
modulating GI disease (especially in motility disorders), although 
it is still not clearly understood how nNOS dysfunction contributes 
to the pathology (Takahashi, 2003; Pasricha et al., 2008; Gangula 
et al., 2010a,b). Because a precedent already exists for aberrant 
SNO signaling in CNS (Schonhoff et al., 2006), respiratory (Que 
et al., 2005), and cardiovascular disease (Lima et al., 2009), this 
section will consider abnormal S-nitrosylation reactions in gut 
pathophysiology.
Gut motility is controlled by contractile cholinergic and relaxant 
non-adrenergic non-cholinergic (NANC) neurons in the myenteric 
plexus (Lecci et al., 2002). nNOS-generated NO is a primary inhibi-
tory NANC neurotransmitter, and aberrant NANC relaxation is 
cysteine β93 on hemoglobin, which is allosterically regulated by 
oxygen tension, i.e., R versus T states. This allosteric mechanism 
facilitates carriage of vasodilatory NO to capillaries in oxygen 
deprived tissues (Foster et al., 2009). Our laboratory has recently 
demonstrated that allosteric S-nitrosylation reactions may also 
regulate toxin-induced neurogenic inflammation in the colon 
(unpublished data). As a specific example, Clostridium difficile 
toxins have evolved an elegant virulence mechanism to enter 
host cells by exploiting the allosteric cytosolic cofactor inositol 
hexakisphosphate (InsP
6
; Reineke et al., 2007). To combat this 
virulence mechanism, inflammation-induced SNO functions as 
a novel host defense mechanism by competitively inactivating a 
critical catalytic cysteine on the toxin during allosteric coupling 
by InsP
6
. Thus, elevated NOS activity in response to neurogenic 
inflammation promotes cellular SNO accumulation within the 
highly lipophilic plasma membrane microenvironment that sub-
sequently inhibits toxin entry.
locaTion, locaTion, locaTion….also applies To sno-regulaTion
Intracellular compartmentalization of target proteins is another 
important regulatory mechanism for S-nitrosylation (Iwakiri 
et al., 2006). For example, the mitochondrial microenvironment 
is enriched with inorganic electron acceptors, such as NAD+ and 
cytochrome c, which promote SNO formation and play an impor-
tant regulatory role in caspase activation during apoptosis. Inactive 
pro-caspase 3 remains constitutively S-nitrosylated in the inner 
mitochondrial membrane. Once this protein is shuttled into the 
highly reducing microenvironment of the cytosol, it is rapidly 
denitrosylated into an active form (Rössig et al., 1999; Mannick 
et al., 2001). Therefore, reductive and enzymatic denitrosylation 
represent important physiological steps in NO signal transduction 
since the SNO-bond is otherwise a reasonably stable modification 
[Benhar et al., 2008; a theoretical half-life of seconds to years is 
evident for homolytic bond dissociation energies (22–32 kcal) for 
the S–N bond in SNOs]. However, not all proteins are rapidly deni-
trosylated in the cytosolic microenvironment, especially when the 
modified cysteine residue is located within a hydrophobic pocket. 
For example, extracellular signal-regulated kinase (ERK) remains 
S-nitrosylated even after prolonged exposure to powerful reducing 
agents (Paige et al., 2008).
sno modulaTion of neuronal plasTiciTy and signaling
A recent study has demonstrated that endogenous NO regulates 
inhibitory synaptic transmission and neuronal excitability in the 
ileal submucosal plexus (Bornstein et al., 2010). A significant com-
ponent of this NO bioactivity appears to be cGMP-independent 
(J. Bornstein, personal communication), implicating S-nitrosylation 
as a potential postsynaptic regulatory mechanism of inhibitory syn-
apticpotentials (IPSPs), slow excitatory synaptic potentials (EPSPs) 
and action potential firing in submucosal neurons. In the CNS, 
S-nitrosylation is known to regulate neuronal plasticity and signal-
ing by directly modulating protein–protein interactions and neuro-
transmitter release, for example by S-nitrosylating actin (Lu et al., 
2009). Neuronal plasticity is also modulated by SNO-regulation of 
membrane receptor and ion channel activity, such as the surface 
expression of glutamate-stimulated AMPA and NMDA receptors 
(Selvakumar et al., 2009). Because NMDA receptor expression has 
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using fluorescence in a novel unbiased proteomic approach 
(SNOFlo) for characterizing the entire S-nitrosoproteome, we 
have demonstrated that SNO homeostasis is also altered in the 
gastric antrum of nNOS
α
 deficient mice, with different protein 
populations being targeted for S-nitrosylation (unpublished 
findings). However, as significant quantities of protein–SNO 
are still measurable in the stomach of nNOS
α
 deficient mice, 
regulation of the SNO pool appears to be more complex in the 
GI tract. This apparent disparity between nNOS activity and SNO 
accumulation may be due, in part, to bioactive SNO being gener-
ated and stored as stable intermediates following dietary nitrite 
conversion in the gut lumen (Suscheck et al., 2006; Figure 1). 
An estimated 20% of the total body NO production may occur 
from dietary nitrite reaction with gastric acid in the stomach 
Kuhnle et al., 2007; Milkowski et al., 2010), and the resulting 
stable SNO pool is sufficiently large to induce smooth muscle 
relaxation in the gastric fundus (Ogulener and Ergun, 2002). 
Bioactive SNO may also be generated from foods that are rich 
in heme-containing red meat which contains significant SNO-
synthase activity. Dietary SNO has been implicated in colorectal 
cancer progression (Milkowski et al., 2010), but potentially may 
also play a significant role in regulating nNOS activity and neu-
ronal cell death in the GI tract.
Diabetic autonomic neuropathy represents one interesting dis-
ease showcase because nNOS deficiency in diabetic gastropathy 
would be expected to slow gastric emptying, yet paradoxically this 
may also promote greater conversion of dietary nitrite into SNO. 
Diabetic gastropathy is thought to results from an impairment of 
nitrergic neurons that undergo a progressive loss of nNOS activity, 
followed by a degenerative process (Watkins et al., 2000; Cellek 
et al., 2003; Surendran and Kondapaka, 2005; Iwasaki et al., 2006; 
Shotton et al., 2006; Pasricha et al., 2008; Gangula et al., 2010a,b). 
In light of the evidence that elevated S-nitrosylation can impair 
insulin receptor β and insulin receptor substrate-1 signaling in dia-
betes (Carvalho-Filho et al., 2005; Kaneki et al., 2007), it is feasible 
that SNO-induced neurotoxicity may also contribute to neuronal 
degeneration. Mechanistically, progressive changes could occur at 
several levels: (i) by modulating nNOS gene expression, (ii) by 
auto-inhibiting nNOS activity, and (iii) by promoting preferential 
apoptosis of nitrergic neurons.
Transcriptional modulation by Sp-1 is known to be regulated by 
the endogenous S-nitrosylation agent GSNO (Zaman et al., 2004). 
Moderate GSNO concentrations augment Sp-1 and Sp-3 binding 
to GC-rich promoter Sp-binding sites, as described for nNOS in 
Section “Regulation of nNOS Activity as a Cellular Source of SNO 
in the Enteric Nervous System.” Further, transcriptional regulation 
by GSNO is not mediated by guanylyl cyclase activation, but appears 
to result from S-nitrosylation of cysteines in the zinc-finger binding 
domain of Sp-1 as it is fully reversible by reducing agents and by 
inhibition of cellular GSNO uptake. By contrast, excessive GSNO 
concentrations can inhibit this transcriptional activity, and it is 
possible that nNOS expression is similarly attenuated by excessive 
GSNO production. Elevated SNO signals may also inhibit nNOS 
activity by post-translational auto-inhibition, as described for CNS 
neurons in Section “SNO Effector Signals in the Enteric Nervous 
System,” or by desensitization of cGMP receptor signaling cascades 
(Mayer et al., 2009).
implicated in the pathophysiology of functional GI motility disor-
ders (Takahashi, 2003; Pasricha et al., 2008; Gangula et al., 2010a,b). 
The functional importance of NO signaling in gut motility has been 
clearly demonstrated following genetic ablation of NO-sensitive 
guanylyl cyclase in mice (Friebe et al., 2007). A subgroup of these 
transgenic pups develops fatal GI obstruction due to a grossly 
enlarged and dilated cecum. Thus, it seems plausible that aber-
rant nNOS activity could contribute to GI pathology, although 
other important transmitter molecules are also likely to orchestrate 
NANC inhibitory signals (Lecci et al., 2002; Vanden Berghe, 2008).
aberranT nnos expression and inTesTinal paThology
Several transcription factors required for nNOS expression, nota-
bly Sp-1, NFκB, and glucocorticoid response elements, are also 
important regulators of intestinal disease and of the stress response. 
Not surprisingly therefore, aberrant nNOS expression is evident in 
several important clinical conditions, including achalasia (Mearin 
et al., 2006; Zarate et al., 2006) and diabetic gastroparesis (Watkins 
et al., 2000; Cellek et al., 2003; Surendran and Kondapaka, 2005; 
Iwasaki et al., 2006; Shotton et al., 2006). Altered NO signaling 
is also present in patients with functional dyspepsia, although 
it is unclear whether this is due to a reduction in NO release or 
nNOS expression in the gastric myenteric plexus (Tack et al., 2002; 
Walecka-Kapica et al., 2007). A deficiency in nNOS innervation may 
contribute to the pathogenesis of aperistalsis of the esophagus in 
patients with congenital esophageal stenosis. Infantile hypertrophic 
pyloric stenosis is also associated with decreased nNOS expression 
in the hypertrophied circular muscle sphincter (Takahashi, 2003). 
In addition, during pregnancy delayed gastric emptying may in part 
be due to abnormal NO activity (Shah et al., 2001). A pathogenic 
role has also been suggested in aging, where nNOS expression and 
activity decreases in the large intestine (Gabella, 1989). However, 
although aberrant nNOS activity is widely implicated in several 
important gut diseases, virtually nothing is known about whether 
this translates into altered SNO signals.
sno signals and s-niTrosylaTion of molecular disease 
TargeTs
There is now an increasing appreciation that altered SNO homeos-
tasis resulting in aberrant S-nitrosylation of regulatory proteins is 
sufficient to contribute to disease severity (Nakamura and Lipton, 
2008; Stamler and Hess, 2010). For example, S-nitrosylation of 
Cys644 on dynamin-related protein 1 causes significant neuro-
nal loss in Alzheimer’s disease (Cho et al., 2009). GAPDH (Hara 
et al., 2005), Parkin (Chung et al., 2004), peroxiredoxin-2 (Fang 
et al., 2007), and protein disulfide isomerase (Uehara et al., 2006) 
are other regulatory proteins that are aberrantly S-nitrosylated in 
Parkinson’s and Alzheimer’s disease. In amyotrophic lateral sclero-
sis, altered denitrosylating activity of mutant SOD-1 is implicated 
in the disease process (Johnson et al., 2001; Schonhoff et al., 2006). 
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